888-794-0077 info@advancedtherapies.com
  • Twitter
  • Twitter
WuXi Advanced Therapies
  • Manufacturing
    • Phase
      • Clinical Manufacturing
      • Commercial Manufacturing
    • Platforms
      • AAV Vector Suspension
      • Lentiviral Vector
      • Closed Process CAR-T
    • Products
      • Cell Banks
      • Cellular Therapies
      • Viral Products
      • Plasmid Manufacturing
  • Testing
    • Services
      • Analytical Development
      • Cell Line Characterization
      • Lot Release
      • Materials Characterization
      • Viral Clearance Validation
    • Products
      • Advanced Therapies
      • Protein Therapies
      • Vaccines
  • Resources
    • Customer Toolbox
    • Knowlege Library
  • About Us
    • Our Story
    • Careers
    • News
    • Locations
    • Events
  • Contact
    • Sales
    • Support
Select Page

By using this site, you agree to our updated Privacy and Cookie Policy.

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

Dec 1, 2020

December 1, 2020 – Philadelphia, PA and Munich, Germany – ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to...

WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory

Nov 18, 2020

The new laboratory will increase industry testing capacity for cell and gene therapies, enabling faster and more effective development, manufacturing and delivery to patients. November 18, 2020 – Philadelphia, PA – WuXi Advanced Therapies Inc. (WuXi ATU) –...

The Healthcare Technology Report Selected Dr. David Chang, Chief Executive Officer, WuXi Advanced Therapies, for The Top 25 Healthcare Technology CEOs of Asia for 2020

Nov 16, 2020

The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology CEOs of Asia for 2020. Asia’s healthtech market has continued its rapid growth with a select group of leaders and their companies standing out for their demonstrated operational...

WuXi Advanced Therapies Appoints Dr. Diya Ren as Executive Director of CMC

Oct 19, 2020

October 19, 2020 – Philadelphia, PA – We are pleased to announce that Dr. Diya Ren will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Executive Director of CMC, effective October 19, 2020. Dr. Ren brings extensive biopharma industry experience in...

WuXi Advanced Therapies Appoints Jennifer Cheung as VP of Quality Assurance and Regulatory Affairs

Oct 5, 2020

October 5, 2020 – Philadelphia, PA – We are pleased to announce that Jennifer Cheung will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Vice President of Quality Assurance and Regulatory Affairs effective October 5, 2020. Ms. Cheung brings a diverse...

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

Jun 1, 2020

SHANGHAI and PHILADELPHIA, June 1, 2020 — WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced...
« Older Entries

Categories

  • Events
  • News
  • Terms of Use
  • Privacy Policy
  • Quality
Accelerating Progress and Time to Market
  • Twitter
© Copyright 2020 WuXi AppTec. All Rights Reserved.